Latest news with #ColorectalCancer
Yahoo
a day ago
- Health
- Yahoo
Gastrointestinal cancers rising dramatically in people under 50
Gastrointestinal cancers, which include colorectal, stomach and pancreatic cancer, are rising dramatically in younger adults, though doctors aren't fully sure why. Even some of the possible causes require more research, they say. According to a review published Thursday in JAMA, gastrointestinal cancers have become the fastest-growing type of cancers diagnosed in adults younger than 50 in the U.S.. The review, one of the most comprehensive looks at gastrointestinal cancer trends, summarized the findings of major international and U.S. cancer databases, plus 115 papers on gastrointestinal cancers published from January 2014 to March 2025. The authors underscore the need for people to follow the screening guidelines for colorectal cancer, which suggest that people with an average risk start screening — usually a colonoscopy or stool test — at age 45. Since doctors don't routinely screen for pancreatic, stomach and esophageal cancers in the U.S., the authors also call for new ways to screen more people for these cancers. 'This really points to the importance of trying to improve screening and early detection,' said Dr. Kimmie Ng, the review's co-author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute. According to the review, colorectal cancer is by far the most common early-onset gastrointestinal cancer, with nearly 185,000 cases reported worldwide in 2022 and nearly 21,000 cases reported that same year in the U.S. Diagnoses in the U.S. have risen 2% annually in people younger than 50 since 2011, according to the American Cancer Society. 'It never used to happen in this age group, and now a very significant rise in 20, 30 and 40-year-olds are getting colon cancer,' said Dr. John Marshall, chief medical consultant at the nonprofit Colorectal Cancer Alliance, who was not involved in the research. In one of the most high-profile examples, actor Chadwick Boseman was diagnosed with colon cancer in 2016 and passed away of the disease four years later at age 43. Early-onset cases of pancreatic, stomach and esophageal cancers are also rising, according to the new study. Previous research has shown a disproportionate share of those gastrointestinal cancer diagnoses were among Black and Hispanic people. Pancreatic cancer is among the deadliest forms of cancer, with just 13% of patients surviving five years after their diagnosis. Because colorectal cancer is the most common, doctors said they have a better grasp of what might be contributing to these early-onset cases compared to others. 'If we can understand what's going on in colorectal [cancer], I think it would really provide a lot of guidance to help us understand the other GI tract cancers,' said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center. Kopetz said there are likely multiple factors driving the increase in early-onset cases. 'The leading theory is that there is no single leading theory,' he said. Ng's new review in JAMA suggests that most gastrointestinal cancers in people under 50 are associated with lifestyle factors such as obesity, lack of exercise, poor diet, cigarette smoking or alcohol consumption. One study included in the review found that women who consumed more sugar-sweetened beverages during adolescence had a higher risk of developing early onset colorectal cancer. 'It's really what people were doing or exposed to when they were infants, children, adolescents that is probably contributing to their risk of developing cancer as a young adult,' Ng said. Health and Human Services Secretary Robert F. Kennedy Jr. has been vocal about the association between sugary beverages and health issues, including cancer. On Wednesday, President Donald Trump said Coca-Cola will start being made with cane sugar rather than corn syrup in the U.S., but the company did not commit to the change when asked about it by NBC News. Marshall said he suspects the rise in early-onset colorectal cancer could have something to do with changes in people's gut microbiomes — the bacteria that live in our gastrointestinal tracts. Diet, antibiotic use, microplastics and exposure to environmental chemicals likely all influence a person's gut bacteria, but scientists still don't have a clear understanding of what a healthy microbiome looks like nor how it affects our health. That is a booming area of research. Ng's review also found that 15% to 30% of people with early-onset gastrointestinal cancer carry hereditary genetic mutations that may have predisposed them to getting cancer at a young age. Because of that, she said, 'we do recommend that all young patients diagnosed under the age of 50 undergo testing for hereditary conditions.' Overall survival rates for gastrointestinal cancers have gotten better over time, due to improvements in treatment and screening. But Ng's review found that younger patients often have worse outcomes, despite typically receiving more treatments, including more surgery, radiation and aggressive combinations of chemotherapy, she said. One reason could be that primary care doctors may overlook symptoms such as abdominal pain, constipation, heartburn or reflux in younger patients, thereby delaying their diagnoses. 'My personal feeling is that it's because we're finding them at a more advanced stage, because people don't really think of colon or other GI cancers when they see a young person with these non-specific complaints,' said Dr. Howard Hochster, director of gastrointestinal oncology at Rutgers Cancer Institute and RWJBarnabas Health in New Jersey. But Ng said that even after controlling for the stage at which patients are diagnosed, young people still seem to have worse survival rates. 'This makes us wonder as researchers whether that means that the cancers that develop in younger people may be biologically different and more aggressive, or maybe less responsive to treatment,' she said. This article was originally published on Solve the daily Crossword
Yahoo
09-07-2025
- Health
- Yahoo
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials
PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ('LIXTE' or the 'Company') (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE's ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers ( A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy ( identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors. Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE's lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses. LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients. 'Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types,' said Dr. Jazaeri, who was co-senior author of the Nature article. 'Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson.' Bas van der Baan, LIXTE's Chief Scientific Officer, added, 'This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year.' About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at Forward-Looking Statement Disclaimer This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors. Readers are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission at The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information about LIXTE, Contact: For more information about LIXTE, Contact: info@ General Phone: (631) 830-7092; Investor Phone: (888) 289-5533orPondelWilkinson Inc. Investor Relations pwinvestor@ Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Associated Press
01-06-2025
- Business
- Associated Press
World-first clinical trial confirms exercise improves survival for colon cancer
A Canadian Cancer Society-funded trial reveals that guided exercise can save and prolong lives by reducing risk of cancer recurrence and second cancers TORONTO, June 1, 2025 /CNW/ - A groundbreaking clinical trial funded by the Canadian Cancer Society (CCS) shows that physical activity can significantly improve outcomes for people with colon cancer. Researchers say the study is the first in the world to use structured exercise to increase cancer survival. The trial results, presented today at the American Society of Clinical Oncology annual conference and published in the New England Journal of Medicine, have the potential to change clinical practice. They show that, when incorporated into cancer care for people with colon cancer, a structured exercise program reduces the risk of cancer recurrence and of new primary cancers developing. 'Our findings show that exercise is no longer just a quality-of-life intervention for cancer patients that can be offered when and where possible,' says study co-chair Dr Kerry Courneya, a professor of kinesiology at the University of Alberta and Canada Research Chair in Physical Activity and Cancer. 'It is a treatment for colon cancer that must be made available to all patients.' Colorectal cancer is the second leading cause of cancer death in Canada. Last year, an estimated 25,200 Canadians were diagnosed with colorectal cancer and 9,400 people died from it. To improve outcomes, a team led by Dr Courneya and Dr Chris Booth – study co-chair, medical oncologist at Kingston Health Sciences Centre and professor of oncology at Queen's University – has been working with the Canadian Cancer Trials Group (CCTG) on this first-of-its kind trial. The 17-year international trial involved 889 people, all of whom had been diagnosed with and treated for colon cancer. After having surgery and chemotherapy, participants were given a 3-year structured exercise program or standard health education materials that are currently given to patients. Each participant in the exercise program chose their own forms of moderate-intensity exercise – from walking to pickleball – with the goal of adding 2.5 hours of exercise per week to their regular activity schedule. The outcome: those who received the exercise program had a 28% lower risk of recurrence and new cancers and a 37% lower risk of death. 'This is the first clinical trial in the world designed to answer whether exercise can improve cancer survival, and the results are clear,' says Dr Booth. 'The next step is to put this into practice. That means health systems will need to invest in behaviour support programs as part of standard care.' The researchers are currently conducting a comprehensive health economic analysis. According to Dr Booth, they anticipate that the program will be 'remarkably cost-effective compared to many new cancer drugs,' making it sustainable for health systems. Terri's story Terri Swain-Collins was diagnosed with stage 3 colon cancer in 2021 after a screening test led to further investigation. Following treatment including surgery and chemotherapy, she was invited to join Dr Booth and Dr Courneya's clinical trial. During the trial, she worked closely with a physiotherapist to establish and maintain a fitness routine personalized to her needs. 'One of the biggest benefits was having a semi-structured routine that works for my lifestyle with someone to hold me accountable,' says Terri. 'Simply being told to exercise by a physician wouldn't have been enough to get me to where I am today; having someone walk alongside me, guide me and check in regularly was what truly made it possible.' Now, 3 years later, Terri continues to walk 3 times a week, feels fit and remains cancer-free. She says she is grateful for the impact of the program on her health and well-being. 'By bridging the gap between bold ideas and routine practice, clinical trials are essential to driving research progress that can benefit patients,' says Dr Stuart Edmonds, Executive Vice President, Mission, Research and Advocacy at CCS. 'The results of this trial have the potential to save and improve lives for the tens of thousands of people in Canada affected by colorectal cancer each year, and we are proud our donors enabled us to support it.' The international study co-chair was Dr Janette Vardy, from The University of Sydney (Australia) with funding from National Health and Medical Research Council. The UK team was led by Dr Victoria Coyle at Queen's University of Belfast, supported by Cancer Research UK. About the Canadian Cancer Society The Canadian Cancer Society works tirelessly to save and improve lives. We raise funds to fuel the brightest minds in cancer research. We provide a compassionate support system for all those affected by cancer, across Canada and for all types of cancer. Together with patients, supporters, donors and volunteers, we work to create a healthier future for everyone. Because to take on cancer, it takes all of us. It takes a society. Help us make a difference. Call 1-888-939-3333 or visit today. About the Canadian Cancer Trials Group The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies at over 85 hospitals and cancer centres across Canada. From their operations centre at Queen's University, CCTG has supported more than 600 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG's aim is to improve survival and quality of life for all people with cancer. Learn more at SOURCE Canadian Cancer Society (National Office)
Biz Bahrain
12-05-2025
- Health
- Biz Bahrain
RCSI Medical University of Bahrain Advocates for Increased Colorectal Cancer Awareness
The Royal College of Surgeons in Ireland – Medical University of Bahrain organised a public campaign to raise awareness about Colorectal – related to Colon and Rectum- Cancer (CRC) with the support of 150 medical and nursing students. Held in collaboration with the King Hamad University Hospital and the King Hamad American Mission Hospital, this campaign led by Professor Hussain Nasaif, Associate Professor in Nursing and Director of the MSc in Nursing Programme at RCSI Medical University of Bahrain, with the support of the Community Engagement Office, aimed at raising awareness about the early symptoms and risk factors of Colorectal Cancer. As part of this initiative, over 250 individuals who visited both hospitals over the course of four days were demonstrated how CRC develops within the colon by our student volunteers using an inflatable colon model as an effective educational tool. Colorectal – related to Colon and Rectum- Cancer (CRC) continues to pose a significant public health challenge in the Kingdom of Bahrain, with data highlighting the increase in new cases and the need for improved awareness, early detection and preventive measures. According to the latest statistics from the World Health Organization's International Agency for Research on Cancer (IARC), Colorectal Cancer emerged in 2022 as the most commonly diagnosed cancer among men in the Kingdom of Bahrain, with an incidence rate of 14.8%. Among women, it is the second most common cancer, following breast cancer, with an incidence rate of 8.2%. When compared with figures from the wider West Asia region—9.7% among men and 8.7% among women—CRC appears more prevalent among Bahraini men, while the rate among women remains broadly similar. Negative lifestyle factors, including smoking, alcohol consumption, obesity, a diet high in processed foods, fatty food, low fibre diet, and physical inactivity significantly contribute to the risk of developing Colorectal Cancer. Conversely, a balanced diet combined with regular physical activity can lower the risk and improve overall health outcomes. Common symptoms of CRC include blood in the stool, incomplete bowel emptying, lower abdominal pain, unexplained weight loss, loss of appetite, fatigue and anaemia. Individuals experiencing these symptoms are advised to consult their family doctor to review their personal and family medical history and explore available CRC screening options. Regular CRC screening is recommended from the age of 45 for both men and women. Early detection dramatically increases the likelihood of successful treatment and patients' survival rate. Professor Sameer Otoom, President of RCSI Medical University of Bahrain, commented: 'We are grateful to our partner hospitals for hosting and supporting our Colorectal Cancer awareness initiative. Our collaborative effort in engaging the public and extending the relevant healthcare services is critical in tackling this prevalent disease for the benefit of all people in the Kingdom of Bahrain. Such partnerships strengthen our mission to enhance community health through education, research, and service.' RCSI Medical University of Bahrain remains committed to empowering the public with the knowledge and resources necessary to reduce the impact of Colorectal Cancer, as well as other prevalent diseases and health conditions. By fostering a culture of education, early detection, and prevention, we continue to play an active role in supporting the health and wellbeing of individuals and communities across the Kingdom of Bahrain.
Zawya
11-05-2025
- Health
- Zawya
RCSI Medical University of Bahrain advocates for increased colorectal cancer awareness
The Royal College of Surgeons in Ireland – Medical University of Bahrain organised a public campaign to raise awareness about Colorectal – related to Colon and Rectum- Cancer (CRC) with the support of 150 medical and nursing students. Held in collaboration with the King Hamad University Hospital and the King Hamad American Mission Hospital, this campaign led by Professor Hussain Nasaif, Associate Professor in Nursing and Director of the MSc in Nursing Programme at RCSI Medical University of Bahrain, with the support of the Community Engagement Office, aimed at raising awareness about the early symptoms and risk factors of Colorectal Cancer. As part of this initiative, over 250 individuals who visited both hospitals over the course of four days were demonstrated how CRC develops within the colon by our student volunteers using an inflatable colon model as an effective educational tool. Colorectal – related to Colon and Rectum- Cancer (CRC) continues to pose a significant public health challenge in the Kingdom of Bahrain, with data highlighting the increase in new cases and the need for improved awareness, early detection and preventive measures. According to the latest statistics from the World Health Organization's International Agency for Research on Cancer (IARC), Colorectal Cancer emerged in 2022 as the most commonly diagnosed cancer among men in the Kingdom of Bahrain, with an incidence rate of 14.8%. Among women, it is the second most common cancer, following breast cancer, with an incidence rate of 8.2%. When compared with figures from the wider West Asia region—9.7% among men and 8.7% among women—CRC appears more prevalent among Bahraini men, while the rate among women remains broadly similar. Negative lifestyle factors, including smoking, alcohol consumption, obesity, a diet high in processed foods, fatty food, low fibre diet, and physical inactivity significantly contribute to the risk of developing Colorectal Cancer. Conversely, a balanced diet combined with regular physical activity can lower the risk and improve overall health outcomes. Common symptoms of CRC include blood in the stool, incomplete bowel emptying, lower abdominal pain, unexplained weight loss, loss of appetite, fatigue and anaemia. Individuals experiencing these symptoms are advised to consult their family doctor to review their personal and family medical history and explore available CRC screening options. Regular CRC screening is recommended from the age of 45 for both men and women. Early detection dramatically increases the likelihood of successful treatment and patients' survival rate. Professor Sameer Otoom, President of RCSI Medical University of Bahrain, commented: 'We are grateful to our partner hospitals for hosting and supporting our Colorectal Cancer awareness initiative. Our collaborative effort in engaging the public and extending the relevant healthcare services is critical in tackling this prevalent disease for the benefit of all people in the Kingdom of Bahrain. Such partnerships strengthen our mission to enhance community health through education, research, and service.' RCSI Medical University of Bahrain remains committed to empowering the public with the knowledge and resources necessary to reduce the impact of Colorectal Cancer, as well as other prevalent diseases and health conditions. By fostering a culture of education, early detection, and prevention, we continue to play an active role in supporting the health and wellbeing of individuals and communities across the Kingdom of Bahrain. About RCSI Medical University of Bahrain RCSI Medical University of Bahrain is a constituent university of the Royal College of Surgeons in Ireland (RCSI), which was established in Dublin, Ireland, in 1784. RCSI Medical University of Bahrain, an independent private university, opened its doors to a cohort of 28 medical students in 2004. Today, the purpose-built campus is home to a student body of more than 1,600 across the Schools of Medicine; Nursing and Midwifery and Postgraduate Studies and Research. It is a not-for-profit health sciences institution focused on education and research to drive positive change in all areas of human health worldwide.
